Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05968898 · ClinicalTrials.gov registry record · NA
Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES
A NA study of Lung Cancer and Pulmonary Nodule, Solitary, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 3
- Study locations
NCT05968898: Recruiting NA study of Lung Cancer and Pulmonary Nodule, Solitary, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05968898 is a NA study of Lung Cancer and Pulmonary Nodule, Solitary that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 300 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (68% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05968898, a NA study of Lung Cancer and Pulmonary Nodule, Solitary, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a pragmatic clinical trial that will study the effect of a radiomics-based computer-aided diagnosis (CAD) tool on clinicians' management of pulmonary nodules (PNs) compared to usual care. Adults aged 35-89 years with 8-30mm PNs evaluated at Penn Medicine PN clinics will undergo 1:1 randomization to one of two groups, defined by the PN malignancy risk stratification strategy used by evaluating clinicians: 1) usual care or 2) usual care + use of a radiomics-based CAD tool.
Primary Outcome
The composite proportion of benign pulmonary nodules managed with imaging surveillance and malignant pulmonary nodules managed with biopsy or empiric treatment. Final pulmonary nodule diagnosis will be categorized as malignant or benign based on pathologic evaluation. If pathology is unavailable or inconclusive (i.e., the biopsy was non-diagnostic), pulmonary nodule resolution, shrinkage, or diameter stability at 12 months will be defined as a benign diagnosis.
Conditions Studied
Interventions
- DEVICE Optellum Virtual Nodule Clinic
Study Locations (3)
Pennsylvania
- Penn Medicine University City - Philadelphia
- Perelman Center for Advanced Medicine - Philadelphia
- Penn Medicine Washington Square - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-01-09 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT05968898 shows while recruiting
NCT05968898 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (68% lower).
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Optellum Virtual Nodule Clinic is the first listed.
NCT05968898 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05968898 about?
NCT05968898 is a clinical study titled "Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES". This is a pragmatic clinical trial that will study the effect of a radiomics-based computer-aided diagnosis (CAD) tool on clinicians' management of pulmonary nodules (PNs) compared to usual care. Adults aged 35-89 years with 8-30mm PNs evaluated at Penn Medicine PN clinics will undergo 1:1 randomiza...
What is the current status of trial NCT05968898?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2024-01-09. Estimated completion is 2027-12-31.
What conditions does trial NCT05968898 study?
This clinical trial studies the following conditions: Lung Cancer, Pulmonary Nodule, Solitary.
What interventions are being tested in trial NCT05968898?
The interventions under investigation include: Optellum Virtual Nodule Clinic (DEVICE).
Who is sponsoring clinical trial NCT05968898?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05968898 being conducted?
This trial has 3 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05968898's enrollment target sits among peer trials
300 99th of 409 higher than 308 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI